16 research outputs found
The Role of the Periaqueductal Gray Matter in Lower Urinary Tract Function
The periaqueductal gray matter (PAG), as one of the mostly preserved evolutionary components of the brain, is an axial structure modulating various important functions of the organism, including autonomic, behavioral, pain, and micturition control. It has a critical role in urinary bladder physiology, with respect to storage and voiding of urine. The PAG has a columnar composition and has extensive connections with its cranially and caudally located components of the central nervous system (CNS). The PAG serves as the control tower of the detrusor and sphincter contractions. It serves as a bridge between the evolutionary higher decision-making brain centers and the lower centers responsible for reflexive micturition. Glutamatergic cells are the main operational neurons in the vlPAG, responsible for the reception and relay of the signals emerging from the bladder, to related brain centers. Functional imaging studies made it possible to clarify the activity of the PAG in voiding and filling phases of micturition, and its connections with various brain centers in living humans. The PAG may be affected in a wide spectrum of disorders, including multiple sclerosis (MS), migraine, stroke, Wernicke's encephalopathy, and idiopathic normal pressure hydrocephalus, all of which may have voiding dysfunction or incontinence, in certain stages of the disease. This emphasizes the importance of this structure for the basic understanding of voiding and storage disorders and makes it a potential candidate for diagnostic and therapeutic interventions.</p
The effect of sacral neuromodulation (SNM) during the tined lead procedure (TLP) on nocturia in patients with overactive bladder syndrome (OAB)
The effect of sacral neuromodulation (SNM) during the tined lead procedure (TLP) on nocturia in patients with overactive bladder syndrome (OAB)
The effect of sacral neuromodulation (SNM) during the tined lead procedure (TLP) on nocturia in patients with overactive bladder syndrome (OAB)
1.5Full digital generat a partir de la base topogràfica 1:5 000. Els fulls d'aquesta sèrie corresponen a la divisió 4 x 4 de la malla de distribució del Mapa topográfico nacional de España 1:50 000. Cada full inclou 2 finestres (Mapa índex de la sèrie; Mapa guia). - Projecció Universal Transversa Mercator (UTM), fus 31, sobre el·lipsoide internacional i datum europeu. Equidistància de les corbes de nivell: 5 m.Imatge digital de 90 x 67 cm1:5 000300 PP
Botulinum toxin A for refractory OAB and idiopathic urinary retention : Can phenotyping improve outcome for patients: ICI-RS 2019?
AIMS: Botulinum toxin A (BTX‐A) is a well‐established treatment for refractory idiopathic overactive bladder (OAB). It has also been used with short‐term success in treating idiopathic urinary retention. However, efficacy and complication rates are variable and predicting those likely to benefit most from treatment would enable personalization of therapy and optimization of outcomes. At the International Consultation on Incontinence‐Research Society (ICI‐RS) meeting in 2019 a Think Tank addressed the question of how we can improve the way we phenotype patients undergoing BTX‐A treatment. METHODS: The Think Tank conducted a literature review and expert consensus meeting focussing on how advances in basic science research of the mechanism of action of BTX‐A, as well as assessment of psychological comorbidity, can be translated into clinical practice to improve patient selection for therapy. RESULTS: Idiopathic OAB and idiopathic urinary retention are heterogenous conditions encompassing several phenotypes with multiple potential pathophysiological mechanisms. Animal models have demonstrated a central nervous system mechanism of action of intravesically injected BTX‐A and this has been confirmed in human functional MRI studies, but whether this tool can be used to predict outcome from treatment remains to be determined. Phenotyping based on psychological comorbidity using validated screening tools should be studied as a way to potentially optimize patient selection for therapy. CONCLUSIONS: Advances in basic science research into the mechanism of action of BTX‐A have improved our understanding of the pathophysiology of OAB and may lead to novel ways to phenotype patients. Psychological assessment is another way in which phenotyping may be improved. Areas for further research are proposed